PMID- 35526074 OWN - NLM STAT- MEDLINE DCOM- 20220510 LR - 20220716 IS - 1478-6362 (Electronic) IS - 1478-6354 (Print) IS - 1478-6354 (Linking) VI - 24 IP - 1 DP - 2022 May 7 TI - Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis. PG - 100 LID - 10.1186/s13075-022-02781-2 [doi] LID - 100 AB - BACKGROUND: Polyunsaturated fatty acid (PUFA) supplementation has been reported to improve disease activity in inflammatory rheumatic diseases (IRDs). However, data are often conflicting and studies insufficiently large to draw conclusions. This systematic literature review and meta-analysis aimed to better estimate the effect of oral supplementation with omega (n)-3 and n-6 PUFA on IRD activity in terms of duration, dose, type, and source. METHODS: The literature was searched in PubMed, EMBASE, and Cochrane Library databases up to October 2020. Studies were reviewed in accordance with PRISMA guidelines. The effect of PUFA supplementation on disease activity was expressed as the standardized mean difference (95% CI). Metaregression and subgroup analyses involved type of IRD, Jadad score, PUFA source (animal or vegetable), and doses. RESULTS: We obtained 42 references; 30 randomized controlled studies were included comparing the effects of PUFA versus control on disease activity (710 IRD patients receiving PUFA supplementation and 710 controls, most with rheumatoid arthritis). We found a significant improvement in pain, swollen and tender joint count, Disease Activity Score in 28 joints, and Health Assessment Questionnaire score in IRD patients receiving PUFA supplementation as compared with controls, with a significant decrease in erythrocyte sedimentation rate but not C-reactive protein level. Although meta-regression revealed no difference by IRD type or source or dose of PUFA supplementation, subgroup analysis revealed more parameters significantly improved with animal- than vegetable-derived PUFAs and 3- to 6-month supplementation. Most studies examined high-dose supplementation (>2 g/day). CONCLUSION: PUFA consumption, especially omega-3 from animal source >2 g/day, may improve IRD activity and might be an adjuvant therapy in rheumatoid arthritis. TRIAL REGISTRATION: The protocol was registered at PROSPERO ( CRD42021253685 ). CI - (c) 2022. The Author(s). FAU - Sigaux, Johanna AU - Sigaux J AUID- ORCID: 0000-0002-6371-740X AD - Department of Rheumatology, Hopital Avicenne, APHP, INSERM U1125, Universite Sorbonne Paris Nord, 125 rue de Stalingrad, 93000, Bobigny, France. johanna.sigaux@aphp.fr. FAU - Mathieu, Sylvain AU - Mathieu S AD - Department of Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France. FAU - Nguyen, Yann AU - Nguyen Y AD - Department of Internal Medicine, Hopital Beaujon, APHP Nord, Universite de Paris, Clichy, France. FAU - Sanchez, Pauline AU - Sanchez P AD - Department of Rheumatology, CHU de Montpellier, University of Montpellier, PhyMedExp, INSERM, CNRS UMR, Montpellier, France. FAU - Letarouilly, Jean-Guillaume AU - Letarouilly JG AD - Department of Rheumatology, CHU Lille, Universite de Lille, Lille, France. FAU - Soubrier, Martin AU - Soubrier M AD - Department of Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France. FAU - Czernichow, Sebastien AU - Czernichow S AD - Department of Nutrition, Specialized Obesity Center, Hopital Europeen Georges Pompidou, Universite de Paris, APHP, Paris, France. AD - Epidemiology and Biostatistics Sorbonne Paris City Center, UMR1153, Institut National de la Sante et de la Recherche Medicale, Paris, France. FAU - Flipo, Rene-Marc AU - Flipo RM AD - Department of Rheumatology, CHU Lille, Universite de Lille, Lille, France. FAU - Sellam, Jeremie AU - Sellam J AD - DMU 3ID, Hopital Saint Antoine, APHP, CRSA Inserm UMRS_938, Sorbonne Universite, Paris, France. FAU - Daien, Claire AU - Daien C AD - Department of Rheumatology, CHU de Montpellier, University of Montpellier, PhyMedExp, INSERM, CNRS UMR, Montpellier, France. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220507 PL - England TA - Arthritis Res Ther JT - Arthritis research & therapy JID - 101154438 RN - 0 (Fatty Acids, Omega-3) RN - 0 (Fatty Acids, Unsaturated) SB - IM MH - Animals MH - *Arthritis, Rheumatoid/drug therapy MH - Dietary Supplements MH - *Fatty Acids, Omega-3 MH - Fatty Acids, Unsaturated/therapeutic use MH - Humans MH - *Rheumatic Diseases/drug therapy PMC - PMC9077862 OTO - NOTNLM OT - Inflammatory rheumatic diseases OT - Meta-analysis OT - Omega-3 OT - Omega-6 OT - Polyunsaturated fatty acids OT - Rheumatoid arthritis OT - Systematic literature review COIS- The authors declare that they have no competing interests. JSi: consulting fees: Sandoz, Novartis; SM: none; YN: none; PS: none; JGL: consulting fees: Semeia; MS: none; SC: consulting fees: Lilly, Janssen, BMS, Fresenius Kabi, Novonordisk, Servier, Bariatek, Fitforme, Mygoodlife; RMF: none; Jse: consulting fees: Roche, Chugai, Pfizer, BMS, MSD, Biogen, Abbvie, Sandoz, Janssen, Novartis, Fresenius Kabi, Sanofi, research grants: Pfizer, MSD, Schwa Medico; CD: consulting fees: Abbvie, Abivax, BMS, Fresenius Kabi, Novartis, Pfizer, Sandoz, Sanofi, Roche- Chugai, UCB. EDAT- 2022/05/08 06:00 MHDA- 2022/05/11 06:00 PMCR- 2022/05/07 CRDT- 2022/05/07 23:41 PHST- 2021/11/02 00:00 [received] PHST- 2022/04/19 00:00 [accepted] PHST- 2022/05/07 23:41 [entrez] PHST- 2022/05/08 06:00 [pubmed] PHST- 2022/05/11 06:00 [medline] PHST- 2022/05/07 00:00 [pmc-release] AID - 10.1186/s13075-022-02781-2 [pii] AID - 2781 [pii] AID - 10.1186/s13075-022-02781-2 [doi] PST - epublish SO - Arthritis Res Ther. 2022 May 7;24(1):100. doi: 10.1186/s13075-022-02781-2.